P/B
2,4
ProQR Therapeutics
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
$221.6M
Market Cap • 10/8/2026
2012
(14 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
Netherlands
Country
Valuation
P/S
10,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,6
EPS
—
Market Cap
Market Cap
221,6M
EV
105,4M
EV/Revenue
4,9
EV/EBITDA
-2,3
EV/EBIT
-2,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-25,3%
Total Yield
-25,3%
Payout
0%
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
247,8%
Capex/Revenue
6,3%
Capex/D&A
41,9%
Capex/OCF
-2,3%
SBC/OCF
—
% PPE
8,9%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
68,8%
CAGR Op. Income 5Y
-2,6%
CAGR Net Income 5Y
-5,6%
CAGR EPS 5Y
-17,7%
CAGR OCF 5Y
2%
Leverage
N.D./EBITDA
2,5
Debt/Equity
0%
Current Ratio
3,5
Quick Ratio
3,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!